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ABSTRACT 
Nucleotide-binding and oligomerization domain (NOD)-
like receptors (NLRs) are evolutionarily conserved intracellular 
PRRs (Pattern Recognition Receptors) that play an important role 
in host defense and physiology. NLRP12 is a NLR protein which 
is expressed predominantly in cells of myeloid origin. Because 
NLRP12 expression is restricted to immune cells and its 
expression is down-regulated in response to pathogens, pathogen 
products and inflammatory cytokines, it has been predicted that 
NLRP12 functions in regulating inflammation and immunity. 
Although NLRP12 was one of the earliest identified NLRPs, its 
precise function(s) is not fully understood as yet. Despite the 
increasing number of publications, the role of NLRP12 remains 
ambiguous because of conflicting results.  
In this PhD thesis, the regulation of NLRP12 promoter 
activity by NF- B, the transcriptional modulation of NLRP12 
expression during myeloid cell lines and primary monocytes 
stimulation/differentiation as well as the effects of NLRP12 over-
expression on the growth of monocytic cell line U937 are 
reported. 
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CHAPTER 1 
INTRODUCTION 
Vertebrates have the immune system to protect themselves 
against infectious agent. The innate and adaptive immune systems 
developed during evolution for immune detection. All vertebrates 
use the innate immune system, however, only jawed vertebrates 
use both innate and adaptive immune systems. Adaptive immune 
cells, such as T and B lymphocytes, in jawed vertebrates can 
express nearly an unlimited number of antigen specific receptors
1
. 
Antigen recognition by these receptors causes lymphocytes to 
undergo clonal proliferation, to generate daughter cells with the 
potential to recognize the same pathogen
2
. These lymphocytes 
form effector cells for clearing the infection and memory cells to 
react quickly upon secondary exposure to the same antigen. While 
the adaptive immune system responses take days to occur, innate 
immune responses occur within minutes to hours
3
, therefore the 
innate immune system is the first line of host defense during 
infection since the early recognition and subsequent triggering of 
a pro-inflammatory response to invading pathogens is crucial. 
However, the adaptive immune system functions in the 
15 
 
elimination of pathogens in the late phase of infection and in the 
generation of long-lasting protective immunity
4
.  
Innate receptors are able to detect highly conserved 
microbial components and respond quickly to a wide range of 
microbial diversity
5. This strategy is called “pattern recognition” 
and relies on a germline encoded, limited set of pattern 
recognition receptors (PRRs). The molecular patterns which are 
detected by PRRs are broadly classified into two categories on the 
basis of their origin: pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs)
6
. 
PAMPs refer to exogenous molecules which are found 
particularly on a group of pathogens. These include patterns such 
as cell wall components, flagella, lipoproteins, and nucleic acids 
of bacterial, fungal, and viral origin
5, 6, 7
. In contrast to PAMPs, 
DAMPs are endogenous molecules which are released or 
modified by the host cell upon stress or damage, like DNA-
binding proteins, heat-shock proteins (HSPs), extracellular ATP, 
and uric acid crystals
7, 8
. 
1.1. PRRs Families 
PRRs are expressed by cells of innate immunity including 
monocytes, macrophages, dendritic cells, endothelial cells and 
neutrophils, as well as cells of the adaptive immunity
9
. PRRs 
located on the cell surface recognize the microbes present in the 
extracellular environment
10
. Cytoplasmic PRRs recognize 
16 
 
intracellular cytosolic pathogens and their derivatives, endosomal 
PRRs interact with microbes that have entered the 
phagolysosomal degradation pathway
5
. The recognition of 
PAMPs or DAMPs by the PRRs initiates an inflammatory 
response including cytokines and chemokines secretion, the 
induction of host defense peptides, pyroptotic cell death and the 
recruitment of phagocytes
11, 12
. 
The PRRs families of the innate immune system are C-
type lectin receptors (CLRs), RIG-I-Like receptors (RLRs), 
Cytosolic DNA sensors (CDSs), Toll-Like receptors (TLRs) and 
Nucleotide binding leucine rich repeat containing receptors which 
also known as NOD-like receptors (NLRs). Each PRRs family has 
a diverse structure and acts differently to detect pathogens and 
generate the appropriate immune responses 
13 
(Fig. 1.1). 
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Fig. 1.1. Schematic representation of PRRs and the downstream signaling 
events:  The PRRs families of the innate immune system are C-type lectin 
receptors, RIG-I-Like receptors, cytosolic DNA sensors, Toll-Like receptors 
and NOD-like receptors. They can recognize PAMPs or endogenous danger 
molecules, DAMPs, and cause activation of several signalling events to 
mediate immun response (Adapted from Shaw, SG. and Tsui, J., 2013)
13
. 
1.1.1. C-Type lectin receptors (CLRs) 
CLRs, also called the C-type lectins, act as phagocytic 
receptors which are critical in recognition of antigens which can 
be of extrinsic origins, such as viruses or other microbes as well as 
18 
 
intrinsic origins such as altered self lipids or proteins
14
. CLRs are 
found in cells which phagocytize various glycoproteins and 
microbes for the purposes of clearance or antigen presentation
12 
(Fig. 1.2).  
Fig. 1.2. Signalling pathways through CLRs: CLR signaling can be activated 
by various numbers of PAMPs. Upon ligand binding, the signaling pathways 
are triggered to activate NF-κB and NLRP3 inflammasome resulting in the 
production of defensins, chemokines, cytokines, and reactive oxygen species 
(Modified from Cunha, C. et al., 2012 )
15
.  
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1.1.2. RIG-I-like receptors (RLRs) 
Another family of cytosolic PRRs is the RIG-I-like 
receptors (RLRs), which are the cytoplasmic sensors for RNA 
viruses. Recognition of viral dsRNA by Toll-Like receptor 3 
(TLR3) or by RLRs is cell-type dependent
16
.  
The members of RLR family contain a DExH-box helicase 
domain that can detect the presence of RNA from a broad range of 
viruses
17
. Following recognition of viral RNA, the subsequent 
signaling cascade results in the induction of transcription factors 
like interferon regulatory factor 3 (IRF3), IRF7, and NF-κB 
(Nuclear Factor B) which leads to the production of type I IFN 
(Interferon). Type I IFN binds to the IFN receptor to initiate the 
expression of interferon-stimulated genes like antiviral proteins, 
immune-proteasome components, members of the TLR family, 
transcription factors like IRF7, various pro-inflammatory 
cytokines and chemokines
4, 16, 17
 (Fig. 1.3). 
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Fig. 1.3. RLRs signaling: Cytosolic dsRNA and 5
’
-triphosphate ssRNA is 
recognized primarily by RIG-I (Retinoic acid-Inducible Gene 1) and MDA5 
(Melanoma Differentiation-Associated protein 5) which then interact with 
mitochondria localized IPS-1 (IFN-β Promoter Stimulator-1). The interaction 
triggers NF- B and IRF3 activation. PKR (protein kinase regulated by RNA) is 
another RLR which recognizes dsRNA and activates MAPKs signalling. 
dsRNA and ssRNA can also be recognized by the Toll like Receptors TLR3 
and  TLR7/8, respectively (Adapted from Mogensen, TH., 2009)
4
. 
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1.1.3. Cytosolic DNA sensors (CDSs) 
The recognition of cytosolic DNA requires several sensors 
which trigger different signaling pathways depending on cell 
types
12
.  
DNA dependent activator of IFN-regulatory factor (DAI) 
binds cytosolic dsDNA and triggers the production of type I IFNs. 
AIM2 (Absent in Melanoma 2) is a cytosolic DNA receptor that 
associates with ASC (Apoptosis-associated speck-like protein 
containing a CARD) through CARD-CARD (Caspase 
Recruitment Domain) interactions to form an inflammasome and 
triggers caspase-1 activation and production of IL-1β (Interleukin-
1β)  and IL-18 (Interleukin-18). In contrast to AIM2, the cytosolic 
dsDNA sensor p202 is a negative regulator of inflammasome 
activity. LRRFIP1 (leucine rich repeat in FLII interacting 
protein1) is another cytosolic dsDNA sensor which leads to 
production of IFN-β in a β-catenin-dependent manner. Although 
RIG-I was a candidate receptor for cytosolic DNA recognition, it 
has been recently shown that rather than the cytosolic DNA, a 
double-stranded RNA intermediate is responsible for RIG-I 
activation
15 ,16, 18
 (Fig. 1.4). 
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Fig. 1.4. Signaling pathways of innate immunity involved in DNA-sensing: 
DNA can be recognized by different sensors, including AIM2, LRRFIP1, DAI, 
and IFI16. Cytosolic DNA from invading viruses and bacteria activate AIM2 
binding to the adaptor ASC for caspase-1 activation and subsequent IL-1β and 
IL-18 production which are important mediators of inflammatory responses to 
infection. LRRFIP1 recognizes dsDNA to induce IFNβ via a β-catenin-IRF3 
trans-activator pathway. DAI induces Tank-binding kinase (TBK1)-IRF3-
dependent IFNβ production following activation by ds B-form or a-typical Z-
form DNA. IFI16 binds to viral DNA, directly and initiate IFNβ induction via 
mitochondria located STING protein (Modified from Herrada, AA. et al., 
2012)
19
.  
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1.1.4. Toll-like receptors (TLRs) 
Among PRRs families, Toll-Like Receptors (TLRs) are the 
first identified and most extensively studied receptors. TLRs 
recognize a variety of bacterial structures like different bacterial 
cell wall components such as lipopolysaccharide (LPS), 
peptidoglycan (PGN) and lipoprotein, as well as bacterial DNA 
and viral RNA or DAMPs which include intracellular proteins 
such as heat shock proteins and extracellular matrix proteins 
released by tissue injury. Stimulation of TLRs by the 
corresponding PAMPs or DAMPs triggers signaling cascades to 
activate transcription factors like AP-1 (activator protein 1), NF-
B and IRFs. The activated transcription factors subsequently 
bind to specific DNA sequences and mediate the production of 
effector molecules such as cytokines, inflammatory enzymes, 
chemokines, and type I IFNs which are important for the 
triggering of the immune response 
5
 (Fig. 1.5). 
The large number of ligands which activate TLRs 
signalling include peptidoglycan, lipoteichoic acid, and zymosan 
(TLR2), lipopolysaccharide (TLR4), double-stranded RNA 
(TLR3), flagellin (TLR5), single-stranded RNA (TLR7 and 
TLR8) and bacterial DNA containing non-methylated CpG motifs 
(TLR9)
20
.  
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Fig. 1.5. TLR signalling: TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 are 
located on the cell surface and TLR3, TLR7, TLR8, and TLR9 are localized to 
the endosomal/lysosomal compartment. TLR signalling is initiated by ligand-
induced dimerization of TLRs. Following the dimerization, the cytoplasmic 
TIR (Toll/IL-1 receptor) domain of the TLR associates with the MyD88 via 
adaptor protein MAL (MYD88-adaptor-like protein) or TRAM (TIR domain-
containing adaptor protein). Engagement of the signalling adaptor molecules 
triggers downstream signalling pathways which induces the production of pro-
inflammatory cytokines and Type I IFNs through the activation of transcription 
factors NF-κB, IRFs, CREB (cAMP Response Element-Binding Protein) and 
AP1 (Adapred from O'Neill, LA., Golenbock, D., and Bowie, AG., 2013)
21
. 
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1.1.5. The NLR family 
Nucleotide-binding and oligomerization domain (NOD)-
like receptors (NLRs) are evolutionarily conserved intracellular 
PRRs that play an important role in host defense and physiology
22
. 
Mammalian NLRs share structural homology to plant disease 
resistance R proteins which mediate plants defense response 
against infection.  The similarity between plant R and animal NLR 
proteins hints that the NLR family represents an ancient family of 
immune defense genes
23, 24
.  
The NLR proteins, in general, have a tripartite domain 
organization: they consist of a central nucleotide-binding and 
oligomerization (NACHT) domain (also known as Nucleotide 
Binding Domain, NBD) which enables the activation of the 
signaling complex via ATP-dependent oligomerization, a C-
terminal leucine-rich repeats (LRRs) domain which functions in 
ligand sensing and autoregulation and a variable N-terminal 
interaction domain which mediates homotypic protein-protein 
interactions for downstream signaling
25, 26
. The mammalian NLRs 
can be divided into four subfamilies, based on different N-
terminal effector domains. The effector domains found in NLRs 
are CARDs, pyrin domains (PYDs), baculoviral inhibitor of 
apoptosis repeat (BIR) domains, or the transactivator domain 
(AD). A standardized nomenclature system categorizes the NLR 
family into four subfamilies based on the initial of the domain 
name: NLRC (formerly known as NODs), NLRP (formerly 
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known as NALPs), NLRB (formerly known as NAIP or Birc) and 
NLRA
27, 28
 (Fig. 1.6). 
NLRs have been most recently discovered family member 
of PRRs and the research field is very dynamic. The research on 
agonists, interaction partners, and signaling pathways of NLRs are 
rapidly increasing. However, different studies may report 
contradicting results and many aspects related to the divergent 
functions of NLRs are not fully understood as yet
29
. 
Fig. 1. 6. Members of human NLRs family: All the members NLRs family 
contains central nucleotide-binding and oligomerization (NACHT) domain, a 
carboxy-terminus leucine-rich repeat domain and a variable amino terminal 
domain. NLRs can be divided into four subfamilies, based on their amino 
terminal domain: (a) The unique NLRA family member is CIITA, (b) the 
NLRB subfamily consists of one member, NAIP (NLR family, apoptosis 
inhibitory protein), (c) members of the NLRP subfamily express an N-terminal 
27 
 
pyrin domain, (d) the NLRC/X subfamily members have either an N-terminal 
caspase recruitment domain (CARD), or an undefined domain that has no 
apparent homology with other proteins (Adapted from Geddes, K. et al., 
2009)
30
. 
1.2. Mechanism of Action of NLRs 
NLR receptor family consists of more than 20 members 
and only about half of them have been characterized in any 
detail
31
. Although it is well known that NLRs play a critical role 
in host defense, it remains unclear how NLRs can recognize 
diverse ligands
22
 even if there is not much evidence to support that 
NLRs directly bind and/or recognize pathogens or pathogen-
derived products
25
. It has been also that the upstream signaling 
receptors or effectors direct the activation of NLRs. Furthermore, 
NLRs might interact with co-receptors or dimerize with additional 
sensors to execute their functions
22
. 
NLRs can be broadly categorized into four groups 
depending on their functions: (1) Trans-activators of transcription, 
(2) Activators of NF- B and mitogen activated protein kinase 
(MAPK), (3) Inflammasome activators, (4) Inhibitors of 
inflammatory signaling
30
. It should be also considered that some 
NLRs are likely to have overlapping functions. Furthermore, 
several NLRs function in pre-implantation and prenatal 
development which indicates that they can play multiple roles 
within inflammation or development and some NLRs might have 
cell type specific alternative roles or they can be activated by 
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multiple activation mechanisms with distinct downstream 
effects
30, 32- 37
. 
1.2.1. CIITA and NLRC5 are the trans-activators of MHC 
expression 
The class II transactivator (CIITA) was the first 
mammalian NLR to be characterized
35
. CIITA is expressed in 
macrophages, B and T lymphocytes and dendritic cells (DCs)
36
. It 
functions as a transcriptional coactivator at the promoter of MHC 
(Major Histocompatibility Complex) class II genes. In 
macrophages and DCs, the alternative splicing mechanism allows 
the production of a CIITA variant equipped with an N-terminal 
CARD domain. The presence of CARD domain is suggested to 
enhance MHC class II gene expression in professional antigen-
presenting cells (APCs)
38
. 
N-terminal activation domain of CIITA is responsible for 
its recruitment to the enhanceosome, a protein complex consisting 
of several nuclear factors including CBP (CREB Binding Protein), 
RFX5 (Regulatory Factor X, 5), NF-Y (Nuclear Factor-Y) and 
CREB that binds cis-acting elements in the MHC class II 
promoter
38
. CIITA is the master regulator of MHC class II 
expression in the enhanceosome, driving transcription of MHC 
class II and MHC class II-linked antigen presentation accessory 
genes like the invariant chain and HLA-DM genes
38, 39
 (Fig. 1.7). 
CIITA is constitutively expressed by immune cells, and its 
expression is significantly induced by IFN-
40
. Type II Bare 
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Lymphocyte Syndrome (BLS), a severe immunodeficiency 
disorder, is caused by the lack of MHC class II expression on the 
cell surface which is the result of the loss of function mutation in 
CIITA
41
.  
Recently, the NLR family member NLRC5 (Nucleotide 
Binding domain and Leucine Rich Repeat Containing 5) was 
shown to transcriptionally activate MHC class I genes as well as 
β2M, TAP1 and LMP2, essential components of MHC class I 
antigen processing and presentation
42
. 
Fig. 1.7. Assembly of CIITA mediated enhanceosome: RFX proteins, CREB 
and NF-Y bind to SXY module which is characteristic of the MHC class II 
gene promoters. The assembly of enhanceosome constitutes a platform for the 
recruitment of CIITA to mediate transcription (Modified from Neerincx, A. et 
al., 2013)
43
. 
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1.2.2. NLRs as activators of NF- B and MAPK 
NOD1 (NLRC1 or CARD4) and NOD2 (NLRC2 or 
CARD15) are the members of NLRs which regulate NF- B and 
MAPK
31
. NOD1 and NOD2 recognize the iE-DAP and MDP 
bacterial peptidoglycans, respectively
44
. Upon ligand binding, 
NOD1 and NOD2 undergo conformational changes and self-
oligomerization via the central NOD domain, followed by the 
recruitment and activation of the serine threonine kinase RICK 
(RIP2) by CARD-CARD interactions
25
. Assembly of NOD1 and 
NOD2 signalosomes result in the activation of NF-κB and 
MAPKs which drives the up-regulation of pro-inflammatory 
genes
45
. 
NOD2 has recently been described as having other roles 
besides its well characterized role in RIP2-dependent NF-κB 
activation. There are multiple reports which demostrate that 
NOD2 can respond to cytosolic RNA during viral infection and 
potentiates antiviral signaling
38, 44
. In addition, NOD2 has been 
shown to interact with c-Rel in T lymphocytes, resulting in the 
decreased nuclear accumulation of c-Rel and impaired IL-2 
transcription
38
. NOD1 and NOD2 also stimulate autophagy in 
response to invasive bacteria independently of RIP2 and NF-κB 
signaling
6
. These observations indicate the relevance of NOD1 
and NOD2 in immunity. Indeed, NOD1 and NOD2 have been 
implicated in a number of chronic inflammatory diseases
46
. 
Mutations in NOD2 have been linked to Crohn’s disease, an 
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inflammatory disease of the intestine, and Blau’s syndrome, a 
familial granulomatous disease characterized by inflammation of 
the eyes, joints and skin
47
. Morever, mutations in NOD1 are 
associated with several inflammatory disorders such as 
inflammatory bowel disease (IBD), asthma, and sarcoidosis
22
. 
1.2.3. NLRs and the Inflammasome 
The sensing of PAMPs and DAMPs by NLR proteins can 
also result in the assembly of a caspase-1 activating multiprotein 
complex referred as inflammasome
48
. Inflammasome formation 
leads to auto-activation of caspase-1 which proteolytically 
activates the potent pro-inflammatory cytokines interleukin-1β 
(IL-1β) and IL-1849. IL-1β and IL-18 activate NF- B, JNK, and 
p38 MAPK signaling pathways to induce the expression of pro-
inflammatory cytokines and chemokines that recruit immune cells 
to the site of infection or injury and lead to pathogen phagocytosis 
or removal of danger signal, resulting in the resolution of infection 
and/or cell death
50
.  
A number of NLR family members have been shown to 
exhibit inflammasome activity in vitro; but only a few NLR 
proteins have clear functions in vivo in the inflammasome 
formation9. NLRP1, NLRP3, NLRC4 (also known as IPAF) and 
NAIP5 (also called as BIRC1 or NLRB1) are the best known 
NLRs playing a role in inflammasome
48 ,51, 52
 (Fig. 1.8). The 
particular NLR involved in inflammasome formation appears to 
be stimulus-specific. For example, the NLRC4 inflammasome is 
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formed in response to multiple Gram-negative bacteria expressing 
flagellin while NLRP3 inflammasome has been shown to respond 
to a variety of pathogens and host derived molecules
53
. Recently, 
an inflammasome complex consisting of NOD2, NLRP1 and 
caspase-1 has been revealed. Considering the well known role of 
NOD2 in NF-κB activation, it has been hypothesized that this 
heterogeous inflammasome couples transcriptional activation of 
inflammatory genes with IL-1β production. Additional studies 
will be likely to reveal the presence of other heterogenous 
inflammasomes and to describe the interactions between certain 
elicitors and NLR proteins
48
. 
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Fig. 1.8. Inflammasome activation: The various inflammasomes are activated 
by a wide spectrum of DAMPs and PAMPs. NLRP3 activation and 
inflammasome formation is depicted as an example. Signal 1 is represented by 
microbial molecules or endogenous cytokines and is required for the up-
regulation of NLRP3 and pro-IL-1β by NF- B. NLRP3 inflammasome is 
activated by various mechanisms like K
+
 efflux, lysosomal damage and 
reactive oxygen species (ROS) production (second signal). Once activated, 
NLRP3 undergoes a conformational change, NLRP3 binds ASC via pyrin 
domain. ASC acts as an adaptor protein and binds to procaspase-1 through 
CARD domain. This large complex is termed the inflammasome and provides 
the platform for the autoactivation of caspase-1 by proteolytic cleavage. Active 
caspase-1 then cleaves pro-forms of IL-1β and IL-18 for their secretion and 
biological activity (Adapted from Anand, PK. et al., 2011)
54
. 
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1.2.4. NLRs with inhibitory functions 
Among the members of the NLRP subfamily, NLRP2, 
NLRC3, NLRP4, NLRP10, NLRP6 and NLRP12, play inhibitory 
roles during inflammation by suppressing distinct arms of 
inflammatory signaling pathways
31, 55
. How these proteins are 
activated or perform their inhibitory functions is not well 
understood as yet
31
. 
1.3. NLRP12  
1.3.1. Identification and expression 
NLRP12, also named RNO, PYPAF7, and Monarch-1, is a 
pyrin-containing NLR protein
56. A partial 3’ portion of the gene 
was first identified in the HL60 human leukemic cell line. Since 
the gene was upregulated when HL60 cells were stimulated with 
nitric oxide, it was first named rno (Regulated by Nitric Oxide)
56, 
57
. The full-length gene was cloned by two groups and named as 
Monarch-1 and PYPAF7, subsequently
58, 59
. The HUGO Gene 
Nomenclature Committee (HGNC) approved the designation 
NLRP12 for this gene. 
NLRP12 encodes an intracellular protein which contains 
an N-terminal pyrin domain, a NACHT-associated domain, and a 
C-terminus leucine-rich repeat region, encoded by 10 exons
60
. The 
full-length human NLRP12 cDNA is 3186-bp long (NCBI 
Reference Sequence: NM_144687.3). There are four known 
alternatively spliced transcript variants encoding distinct isoforms 
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of NLRP12, however if these splice forms are differentially 
expressed and/or serve different functions from the full-length 
product, has not been determined
61
. Human NLRP12 is expressed 
exclusively in cells of myeloid lineage: neutrophils, eosinophils, 
monocytes, macrophages, and immature dendritic cells
62
. 
NLRP12 expression is down-regulated in response to pathogens, 
pathogen products, and inflammatory cytokines
58, 64
. Partial down-
regulation of NLRP12 promoter after TLR stimulation is achieved 
by binding of B lymphocyte-induced maturation protein-1 (Blimp-
1)
65
. NLRP12 has been shown to interact with Hsp70 and Hsp90 
chaperones and these interactions are important for NLRP12 
stability
66
. 
1.3.2 Function 
Since the expression of NLRP12 is restricted to immune 
cells and its expression is down-regulated in response to 
pathogens, pathogen products, and inflammatory cytokines, it has 
been predicted that NLRP12 functions in regulating inflammation 
and immunity
59, 64, 67
.  
The very first report describes that, when it is over-
expressed in non-immune cells, NLRP12 co-localizes with ASC 
and activates NF-κB and caspase-1, leading to IL-1β secretion59. 
However, all subsequent publications suggested a negative 
regulatory role. In one of these studies, endogenous NLRP12 
expression was silenced in the human monocytic cell line THP-1, 
using siRNA. Compared to cells treated with a control siRNA, 
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NFκB activation is enhanced in NLRP12-silenced cells. 
Furthermore, when stimulated with TNFα (Tumor Necrosis Factor 
α), TLR ligands and whole bacteria, NLRP12-silenced cells 
produced a greater amount of NF-κB -regulated pro-inflammatory 
cytokines, such as IL-6, IL-8, IL-1β and TNFα52.  
There are two signaling pathways leading to the activation 
of NF-κB known as the canonical pathway (or classical) and the 
non-canonical pathway (or alternative pathway)
63
 (Fig. 1.19). 
Biochemical studies showed that NLRP12 suppresses pro-
inflammatory cytokine and chemokine production by regulating 
both canonical and non-canonical NF- B activation. Stimulation 
through TLRs leads to the recruitment of cytoplasmic adaptor 
protein MyD88 that then recruits the kinase IRAK1 (Interleukin-1 
receptor-associated kinase 1). The autophosphorylation of IRAK1 
leads to downstream NF-κB activation. Exogenous expression of 
NLRP12 reduces IRAK1-induced activation of an NF-κB 
luciferase reporter plasmid by associating with IRAK1
64
. In 
addition to suppressing canonical NFκB activation, it has been 
also shown that NLRP12 inhibits the non-canonical NF-κB 
pathway. Although nuclear translocation of the canonical NF-κB 
subunits RelA (p65) and p50 proceeds normally after stimulation 
with TLR agonist followed by CD40L, p52 processing from NF-
B2/p100 and nuclear translocation of p52 is abolished in 
NLRP12 over-expressing THP-1 cells. It has been revealed that 
NLRP12 exerts this inhibitory activity by associating with NIK 
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(NF-κB-inducing kinase) and inducing its degradation via the 
proteasome68. Accordingly, NIK, p52 and p52-regulated cytokines 
and chemokines including CXCR4, CXCL12 and CXCL13 levels 
are elevated in NLRP12-silenced cells
68
.  
The inhibitory role of NLRP12 on inflammation and NF-
κB signaling was also supported by in vivo studies. It has been 
shown that Nlrp12
-
/
-
mice are highly susceptible to colon 
inflammation and tumorigenesis with increased production of 
inflammatory cytokines, chemokines, and tumorigenic factors due 
to an excessive NF-κB and ERK (Extracellular signal-regulated 
protein kinase) activation in the macrophages
69
. Furthermore, the 
role of NLRP12 in maintaining intestinal homeostasis and 
providing protection against tumorigenesis were also shown in 
colitis-associated colon cancer model. It has been demonstrated 
that Nlrp12
-
/
-
 mice were highly susceptible to colitis and colitis-
associated colon cancer because of the elevated activation of non-
canonical NF- B, ERK and AKT (also known as protein kinase B 
or PKB) signaling, and increased expression of cancer associated 
target genes including Cxcl12 and Cxcl13
70
. Depending on these 
results, NLRP12 is suggested to be a checkpoint of non-canonical 
NF- B signaling, inflammation, and tumorigenesis. 
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Fig. 1.9. Canonical and non-canonical NF- B pathways: The activation of 
canonical NFkB pathway, represented by IL-1R/TLR stimulation on the left, 
starts with the recruitment of the adaptor protein MyD88 and the kinases 
IRAK1 and IRAK4, leading to oligomerization of E3 ubiquitin ligase TRAF6 
(TNF receptor associated factor 6). Together with the E2 enzyme complex 
Ubc13, TRAF6 synthesizes unanchored K63-polyubiquitin chains that bind to 
the TGF-β-activated kinase 1 (TAK1)-binding protein (TAB)2 and TAB3 
subunits of the TAK1 kinase complex and the NEMO subunit of the IKK 
complex. This binding brings the kinases into proximity for phosphorylation 
and activation. IKK subsequently phosphorylates IκBα. Phosphorylated IκBα is 
targeted for ubiquitin-mediated proteasomal degradation, causing release of the 
NF-κB p65/p50 into the nucleus to regulate the transcription of target genes. 
The activation of non-canonical NF-κB pathway is represented by 
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CD40L/BAFF stimulation on the right.  Stimulation of the surface receptors 
leads to the recruitment of the E3 ligases TRAF2, TRAF3 and cIAPs. TRAF2 
catalyzes K63 polyubiquitination of cIAPs, which in turn target TRAF3 for 
degradation by promoting its K48 polyubiquitination. As a result, TRAF3 level 
in the cell drop below a critical threshold, and NIK can no longer be recruited 
to the cIAPs:TRAF2 complex. In the absence of TRAF3, NIK is stabilized, 
leading to the activation of IKKα which phosphorylates the NF-κB precursor 
p100. Phosphorylated p100 is recognized by the βTrCP E3 complex and 
targeted for ubiquitin-mediated proteasomal processing to form the mature 
subunit p52. p52 forms a complex with RelB, which migrates to the nucleus to 
control gene transcription (Adapted from Liu, S. and Chen, ZJ., 2011)
63
. 
Additionally, NLRP12 has been linked to hereditary 
periodic fever syndrome. The p.Arg284X mutation, located within 
the NBD and the p.Val635ThrfsX12 mutation, located between 
the NBD and LRRs domain of NLRP12, caused lower NF- B 
suppression property compared with the wild type NLRP12
71
.  
The NLRP12 missense mutation p.Asp294Glu was also identified 
in familial cold-induced autoinflammatory syndrome. The 
missense mutation p.Asp294Glu is found within an evolutionarily 
conserved NBD which is fundamental for ATP binding. In 
contrast to the previous findings, no clear reduction of the 
inhibitory properties of the p.Asp294Glu mutant of NLRP12 on 
NF- B signaling was observed
72
. Furthermore, another missense 
mutation (pArg352Cys) within the NBD of NLRP12 in periodic 
fever syndrome patients has also no direct effect on NF- B 
signaling. The mutation, which does not alter the inhibitory effect 
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of NLRP12 on NF-κB activation, increases speck formation and 
activates caspase-1 signaling
73
. 
NLRP12 has also been implicated as an inflammasome 
component recognizing Yersinia pestis. NLRP12 inflammasome 
was shown as an important regulator of IL-18 and IL-1β 
production after Y. pestis infection. NLRP12 also directed IFN-γ 
production, but had minimal effect on signaling of the 
transcription factor NF-κB74. However, in an other study, it has 
been demonstrated that there was no difference in IL-1β 
production in Nlrp12
−/−
 vs wild type bone marrow (BMCs) or 
bone marrow derived dendritic cells (BMDCs) of mice stimulated 
with LPS, LPS together with ATP, other TLR ligands or TNFα56. 
In contrast to previous finding which indicated that silencing of 
NLRP12 with small hairpin RNA leads to increased production of 
IL-6 and TNFα in human cells of monocytic lineage64 , NLRP12 
did not affect the production of pro-inflammatory cytokines IL-12, 
IL-6 and TNFα in response to TLR stimulation56.  
In vivo studies on the functional role of NLRP12 in 
dendritic cells revealed a novel role of NLRP12 in cellular 
migration: dendritic cells and neutrophils from Nlrp12
−/−
 mice 
showed reduced migration (attenuated contact hypersensitivity) 
from the periphery to the draining lymphonodes in vivo and failed 
to respond to chemokines in vitro. On the other hand, NLRP12 did 
not affect dendritic cell maturation neither antigen presentation in 
NLRP12 deficient mice
56
. Despite the findings pointing to an anti-
inflammatory role and the effect on the contact hypersensitivity, 
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NLRP12 did not play a vital role in allergic airway inflammation 
using common model systems that are physiologically relevant to 
human disease
75
. 
The role of NLRP12 during the in vivo host immune 
response to Klebsiella pneumoniae and Mycobacterium 
tuberculosis (Mtb) was also characterized.  As mentioned before, 
NLRP12 has been shown to negatively regulate both canonical 
and non-canonical NF- B pathways in vitro and, more recently, 
has been found to display this role in vivo in colitis and colon 
cancer models. Despite the known effects of both K. pneumoniae 
and Mtb infections on the activation of canonical NF- B 
signaling, no significant differences were observed between 
Nlrp12
-/-
 mice and wild type animals after K. pneumoniae or Mtb 
infections
76
. Together with the in vitro findings which indicate 
NLRP12 as a negative regulator of NF- B signaling after LPS 
stimulation or MTb infection in human THP-1 monocytic cell 
line
64
, recent studies suggest that NLRP12 does not significantly 
contribute to the in vivo host innate immune response to LPS 
stimulation or Mtb infection
76
. Additionally, in response to LPS 
stimulation, Nlrp12 deficient mice showed a slight decrease in IL-
1β and a slight increase in IL-6 production which were not 
statistically significant
76
. These data are consistent with the other 
in vivo findings that also failed to support a role for NLRP12 in 
inflammasome formation
75
. 
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Finally, as distinct from the indicated roles, NLRP12 has 
been suggested to control the expression of classical and non-
classical MHC class I genes in vitro
58
. These findings are 
reminiscent of CIITA and NLRC5 which are the trans-activators 
of MHC class II and MHC class I genes, respectively. 
1.4 Aim of the Work 
Despite the large number of studies, the role of NLRP12 
remains ambiguous. The conflicting results about the functional 
role of NLRP12 can be caused by the differences in the 
experimental systems: NLRP12 can function through 
unpredictable mechanisms, or other proteins can compensate for 
the loss of NLRP12 in an in vivo environment
76
. Furthermore, it is 
also possible that NLRP12 acts temporarily or in a cell type-, 
tissue-, dose- or stimuli-specific manner. Nevertheless, the 
transcriptional regulation of NLRP12 is clear: NLRP12 
transcription is down-regulated following TLR activation or 
exposure of cells to inflammatory cytokines. It is hypothesized 
that the down-regulation of NLRP12 expression is necessary for 
an appropriate immune response. Once the infection has been 
cleared, NLRP12 expression turns back to basal level to prevent 
excessive inflammation and to maintain immune quiescence
38
. 
Based on these statements, I asked whether NF-κB-driven 
negative feedback mechanism induces the down-regulation of 
NLRP12 transcription. Since the expression of NLRP12 is 
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restricted within the immune cells, I have also focused my 
attention on the NLRP12 regulation during myeloid cell 
differentiation. 
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CHAPTER 2 
MATERIALS and METHODS 
2.1 Cell Culture and Differentiation 
HEK293T (Human Embryonic Kidney 293T) and HeLa 
(derived from human cervical cancer cells) cell lines were 
maintained in DMEM (Dulbecco's Modified Eagle's Medium, 
Biochrom) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, 25 U/ml penicillin and 25 U/ml 
streptomycin. Treatment with trypsin-EDTA (Biochrom) was used 
in the passaging of the adherent cell lines. 
The leukemic monocytic cell line U937 was cultured in 
RPMI 1640 (Biochrom) supplemented with 10% heat-inactivated 
FBS, 2 mM L-glutamine, 25 U/ml penicillin, and 25 U/ml 
streptomycin. KG1, the human acute myelogenous leukemia cell 
line, was maintained in IMDM, (Iscove's Modified Dulbecco's 
Medium, Biochrom) containing 20% heat-inactivated FBS, 2 mM 
L-glutamine, 25 U/ml penicillin, and 25 U/ml streptomycin. The 
cells were cultured in a humidified atmosphere of 7% CO2 at 
37°C. 
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Human peripheral blood mononuclear cells (PBMCs) were 
isolated from whole blood of healthy donors using Ficoll density 
gradient centrifugation. Monocytes were enriched from freshly 
isolated PBMC using MACS Monocyte Isolation Kit II and 
MACS LS Columns (Miltenyi Biotec) by depletion of non-
monocytes (negative selection), according to the supplier's 
instruction. The isolated monocytes were adjusted to a 
concentration of 10
6
 cells/ml and were maintained in RPMI 1640 
supplemented with 10% heat-inactivated FBS, 2mM L-glutamine, 
25 U/ml penicillin and 25 U/ml streptomycin in cell culture plates 
at 37°C in a humidified 7% CO2 incubator. Macrophages were 
obtained by incubation of the monocytes for 7 days with 100 
ng/ml of GM-CSF (Granulocyte-Macrophage Colony-Stimulating 
Factor).  Half of the medium was replaced every two days with 
complete fresh medium containing 100 ng/ml GM-CSF (Miltenyi 
Biotec). The differentiation of the myeloid cell lines was achieved 
by the incubation with Phorbol 12-myristate 13-acetate (PMA, 
Sigma-Aldrich) for the indicated times and concentrations. When 
indicated, the proteasome inhibitor MG-132 (Sigma) was used at a 
concentraion of 10 µM, for 6 hours. 
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2.2. Construction of the Plasmids, Transformation and 
Plasmid DNA Isolation 
2.2.1. Generation of NLRP12 promoter constructs 
NLRP12 promoter region was determined by using 
Gene2Promoter, Genomatix Software. The 765 bp long sequence 
of the human NLRP12 promoter was amplified using 5’-
CTGGGTGGCAGAGTGAGAC-3’ as forward and 5’-
TGCCGTGAGCCCCAAAGGAG-3’ as reverse primers, and the 
PCR product cloned into pGL4.10 [luc2] (Promega) promoterless 
luciferase reporter vector by KpnI and XhoI. The construct was 
named as pGL4-NLRP12- full length. The promoter region was 
then cloned into pGL4.10 [luc2] as three separate fragments 
which are named as pGL4-NLRP12-299, pGL4-NLRP12-530 and 
pGL4-NLRP12-765. 
Illustra GFX PCR, DNA and gel band purification kit (GE 
Healthcare) was used for the gel isolation of PCR products and 
digested plasmids, and for the reaction purifications after 
enzymatic digestions, according to the manufacturer's instructions.  
All the ligations were performed overnight at 13°C by T4 
DNA ligase (Bioline). The ligations were transformed into E. coli 
DH10β electro competent cells by electroporation using Bio-Rad 
Gene Pulser. 
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2.2.2. Cloning of human NLRP12 
Full lenght NLRP12 (3186 bp) was amplified from healty 
individual monocyte cDNA by forward 5’-
ATGCTACGAACCGCAGG-3’ and reverse 5’-
CAGCAGCCAATGTCCAAATAAG-3’ primers, using Phusion high 
fidelity DNA polymerase (New England Biolabs, Thermo 
Scientific). HyperLadder™ 1kb (Bioline) was used in this thesis to 
determine the sizes of DNA samples. 
The purified PCR product was ligated by T4 DNA ligase 
(Bioline) to pcDNA3 or pEGFP-N1 expression plasmids, 
maintaining the reading frame. The ligation was performed at 
13°C for overnight. E. coli DH10β electrocompetent cells were 
used for transformation. 
2.2.3. Plasmid DNA isolation 
The transformed E. coli DH10β colonies were grown in 
LB (Luria-Bertani) broth medium containing the appropriate 
antibiotics. All the plasmid DNA isolations were performed using 
Genopure Plasmid Midi Kit (Roche), following the 
manufacturer’s protocols. 
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2.3. Identification of Potential NF-κB Binding Site in the 
NLRP12 Promoter and Site-directed Mutagenesis  
To identify if there was a potential NF-κB binding site 
inside the promoter region, MatInspector, Genomatix Software 
was used. The putative NF-κB binding site was then mutated 
using nested primers, containing mismatched bases. The construct 
was called as pGL4-NLRP12Mut-765. In addition, NF-κB 
“consensus sequence” containing construct was generated, and the 
plasmid construct (pGL4-NLRP12-NFκB-765) was used as a 
positive control in response to NF-κB.  
2.4. Cell Transfections 
2.4.1. Transfection of NLRP12 promoter constructs and 
luciferase assay 
HEK 293T cells were transiently transfected with the 
promoter constructs or empty pGL4.10 [luc2], together with 
expression plasmids for RelA, RelB or a RelA mutant “RelA YA 
ED” which is unable to bind κB site. Lipofectamine 2000 
transfection reagent (Invitrogen) was used for the transient 
transfection of HEK 293T cells.  
pRL-TK (Promega)  renilla luciferase vector was used as 
an internal transfection efficiency control. 48-hours post 
transfection, cells were lysed with Passive Lysis Buffer 
(Promega) and luciferase activity was measured by VICTOR light 
49 
 
luminescence counter (Perkin Elmer) using the Dual-Luciferase 
Assay kit (Promega) according to manufacturer's instructions. The 
luciferase readings were normalized to renilla luciferase. Since the 
pGL4.10 [luc2] vector luciferase expression is up-regulated by 
NF-κB, the normalized luciferase values are plotted as an average 
fold increase over pGL4.10 [luc2] vector.  
2.4.2. Transient and stable transfection of NLRP12 expression 
constructs 
For the expression analysis of pEGFP-N1-NLRP12 
plasmid construct, HeLa cells were transfected transiently with 
pEGFP-N1 (Mock) or pEGFP-N1-NLRP12 plasmids, using 
Lipofectamine 2000 reagent (Invitrogen) according to 
manufacturer's instructions.  
The transfection of U937 cells was achieved by using 
polymer-based Xfect™ Transfection Reagent (Takara). Following 
the gene transfers, cells were cultivated in the culture medium 
containing 2 mg/ml of the selective antibiotic G-418 
(Calbiochem) for 4 weeks. The bulk (mixed population of the 
resistant cells) cells were then also single-cell cloned under G418 
selection. The stable transfectants were maintained in the 
complete growing medium with 1,5 mg/ml G418. NLRP12 
expression was controlled by flow cytometry analysis and qRT-
PCR (Real-Time Quantitative Reverse Transcription PCR). 
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2.5. RNA Isolation and qRT-PCR  
Total RNA was isolated using the Trizol reagent 
(Invitrogen) according to the manufacturer’s protocol. Total RNA 
was used to perform reverse transcription using High-Capacity 
cDNA Reverse Trascription kit (Applied Biosystems) using 
random primers. NLRP12 transcript was analyzed by qRT-PCR 
using sequence-specific TaqMan probe (Hs00536435_m1, 
Applied Biosystems). qRT-PCR performed in ABI PRISM 7300 
Sequence Detection Systems (Applied Biosystems). The 
housekeeping 18S rRNA (TaqMan probe: Hs99999901_s1, 
Applied Biosystems) was used as the endogenous control. 
2.6. Protein Extraction and Western Blotting  
Cell extracts were obtained by incubation of the cell pellets 
in NP40 lysis buffer (20 mM Tris-HCl, pH 8; 137 mM NaCl; 10% 
Glycerol; 1% NP40; 2 mM EDTA) containing protease inhibitors 
(1 mM EGTA; 0,5 mM Na3VO4; 50 mM NaF; 1 mM PMSF; 
1μg/ml Aprotinin; 1μg/ml Leupeptin) for 30 minutes on ice. The 
cellular debris were removed by centrifugation at 13000 rpm for 
15 minutes at 4°C. Protein concentrations were determined by 
Bradford assay (BioRad) and equilibrated amount of samples 
loaded into 8-12% SDS-PAGE (Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis) gels after denaturation in 
SDS sample buffer, at 100°C, for 5 minutes. The separated 
proteins were transferred to a nitrocellulose membrane 
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(AmershamHybond ECL Nitrocellulose Membrane, GE 
Healthcare), which was then blocked in 5% (w/v) non fat dry 
milk powder in 0,1% PBST (v/v, Tween20 PBS) and subsequently 
incubated with the primary antibodies. After several washing 
steps, membranes were incubated with proper secondary 
antibodies conjugated with horseradish peroxidase (HRP). When 
necessary, the membranes were treated with stripping buffer (65,5 
mM Tris-HCl pH 6,8; 100 mM 2-Mercaptoethanol; 2% SDS in 
dH2O) for 30 minutes at 55°C, followed by serial washing steps in 
0,1% PBST. 
The signals were detected by ECL (Enhanced 
chemiluminescence, Amersham) and the images were acquired 
using Molecular Imager ChemiDoc XRS+ System (Bio-Rad). 
ProSieve QuadColor Protein Marker (Lonza) was used as standart. 
For the densitometric analyses, ImageJ 1.46r (NIH) software was 
used. 
The primary antibodies used are the followings: GFP 
Antibody (B-2): sc-9996 (Santa Cruz), cyclin B1 Antibody 
(GNS1): sc-245 (Santa Cruz), cyclin A Antibody (H-432): sc-751 
(Santa Cruz), cyclin D1 Antibody (A-12): sc-8396 (Santa Cruz), 
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) Antibody 
(FL-335): sc-25778 (Santa Cruz). Anti-rabbit IgG, peroxidase-
linked species-specific F(ab′)2 fragment, from donkey 
(Amersham) and Peroxidase-AffiniPure Goat Anti-Mouse 
(Jacksonn ImmnoReserach Laboratories) were used as secondary 
antibodies. 
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2.7. Sample Preparation for Fluorescence Microscopy 
EGFP (Enhanced Green Fluorescent Protein) or EGFP 
fused NLRP12 expressing HeLa cells were grown on the poly-L-
lysine (Sigma) treated cover slips. The cells were fixed-
permeabilized by cold (-20°C) absolute methanol (MetOH) 
treatment for 6 minutes at -20°C. After removal of MetOH, the 
nuclei were stained with DAPI (0.1 µg/ml) for 2 minutes. DAPI 
was removed and the cover slips were rinsed in 1x PBS and 
inverted onto the microscope slides containing 5 µl of mounting 
media (VECTASHIELD mounting media; Vector Laboratories). 
The slides were then allowed to dry and the edges of each 
coverslip were sealed with a regular transparent nail polish and air 
dried. The same sample preparation protocol was used also for the 
pEGFP-N1-NLRP12 expressing U937 cells after “cyto-
centrifuge” which is described below. 
2.8. Immunostaining and Fluorescence Microscopy 
2.8.1. Fixation and permeabilization 
U937 cells were washed in 1x PBS and the cells were 
suspended in 1 ml of 1x PBS containing 10
6
 cells. To attach the 
suspension growing U937 cells to poly-L-lysine treated coverslip 
surface, “cyto-centrifuge” method was used. The cells were 
pipetted onto coverslips and centrifuged starting with 2000 rpm. 
The spin-speed was slowed down to 1000 rpm in 2 minutes, then 
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the cells were centrifuged for additional 10 minutes at 1000 rpm. 
At the end of the centrifuge, PBS was removed and the slides 
were treated with 3,7% formaldehyde (FA), for 15 minutes at 
room temperature (RT). Following the removal of FA, the 
samples were washed 5 minutes in 1xPBS and 5 minutes in 0.25% 
TritonX, subsequently. The samples were then treated with cold (-
20°C) absolute MetOH at -20°C for 10 minutes. MetOH was 
removed and the samples were washed in 1xPBS, for 5 minutes. 
Since the PMA treated (differentiated) U937 cells are adherent, 
the cells were gently detached by a scrapper in cold 1xPBS, 
before the cytocentrifuge. 
2.8.2. Cellular Staining 
After fixation and permeabilization procedures, the cells 
were covered with the blocking buffer composed of 3% BSA 
(Bovine serum albumin) and 0,05% PBST and incubated at RT for 
30 minutes. The blocking buffer was aspirated and the cells were 
incubated with the diluted cyclin B1 antibody (GNS1: sc-245, 
Santa Cruz) for 45 minutes at RT. After removing the primary 
antibody, the samples were washed three times for 5 minutes in 
0,05% PBST and subsequently incubated with the secondary 
antibody (Texas Red anti-mouse, IgG, Vector Laboratories) for 
30 minutes at RT. The nuclei were stained with 0,1 µg/ml DAPI 
solution for 2 minutes at RT. The samples were then washed three 
times in 0,05% PBST, 5 minutes each wash. The cover slips were 
inverted onto the microspe slides containing 5 µl of mounting 
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media (VECTASHIELD mounting media; Vector Laboratories) 
and the slides prepared as above.  
2.8.3. Fluorescence microscopy 
Cyclin B1 stained samples or GFP expressing cells were 
analyzed using a Nikon Eclipse 90i microscope equipped with a 
Qicam Fast 1394 CCD camera (Qimaging), at Nikon Reference 
Centre, CNR Institute of Molecular Biology and Pathology. An oil 
immersion 100x (N.A. 1.3) objective was used and the image 
acquisitions were performed using NIS-Elements AR 3.2 (Nikon). 
2.9. Intracellular Cyclin B1 Staining, DNA Content and Cell 
Cycle Analyses 
2.9.1. Intracellular cyclin B1 staining and DNA content 
analysis 
10
6
 cells were transfered into FACS tubes (Becton, 
Dickinson), washed twice in 1xPBS and suspended in ice cold 300 
µl of 1xPBS. 700 ul of cold (-20ºC) absolute ethanol (EtOH) 
added onto the cells in a dropwise manner and vortexed gently. 
The EtOH fixed cells were incubated at 4ºC for at least 2 hours. 
Before the intracellular staining, the fixed cells were washed 3 
times in 0,5% PBST, for 10 minutes each. To minimize the non-
specific antibody bindings, the cells were incubated in 5% goat 
serum (in 0,5% PBST) for 1 hour at RT. After blocking, the 
samples were incubated with diluted cyclin B1 antibody (H-433: 
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sc-752, Santa Cruz) for 1 hour at RT, then washed three times in 
0,5% PBST. Following the removal of PBST, the cells were 
incubated with diluted secondary antibody (Alexa Fluor 488, 
FITC conjugated anti rabbit IgG, Life Technologies) for 30 
minutes at RT. The secondary antibody was then removed by 3 
times washing in 0,5% PBST, and the samples were incubated in 
25 µg/ml of Propidium iodide (PI, Sigma) in 0,5% PBST for 30 
minutes in the dark at RT, for the DNA content analyses together 
with cyclin B1 expression. Ten thousand events were acquired for 
each sample using a FACStar Plus fluorescence-activated cell 
sorter (Becton, Dickinson) flow cytometer and analyzed by FACS 
WinMDI software. 
2.9.2. Cell cycle analysis 
3x10
5
 cells were washed in 1xPBS and suspended in 300 
µl of PI/Triton X-100 staining solution (50 µg/ml PI; 0,1% Triton 
X-100 in 1xPBS) containing 0,5 mg/ml of DNAse free RNase A 
(Thermo Scientific). The samples were incubated for 15 min at 
37°C in the dark. FACS Calibur (Becton, Dickinson) flow 
cytometer were used for acquisition of the samples. The results 
were analyzed by CellQuest software (Becton, Dickinson). 
2.10. Surface staining and flow cytometry analysis 
The cells were washed in 1xPBS and the samples were 
incubated with FITC conjugated CD11b antibody (Immunotools) 
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for 45 minutes, at 4ºC, in the dark. After the incubation, the cells 
were washed in 1xPBS and analyzed by FACS Calibur (Becton, 
Dickinson) flow cytometer. Analyses were performed using 
CellQuest software (Becton, Dickinson). 
2.11. Statistical Analysis 
The one-way Analysis of Variance (ANOVA) was used to 
determine significance. The asterisks indicate the range of the 
different p values (one asteriks indicates p ≤0.05; two asterisks for 
p ≤0.005). 
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CHAPTER 3 
RESULTS 
In this chapter, results reporting the effect of NF-κB on the 
NLRP12 promoter activity, the transcriptional modulation of 
NLRP12 during myeloid cell differentiation and the effects of 
NLRP12 over-expression on monocytic cell line U937 are 
presented. 
3.1. Analyses of NLRP12 Promoter Activity in Response to 
NF-κB 
3.1.1. Predicted NLRP12 promoter sequence enhances 
luciferase expression  
NLRP12 promoter region is predicted by using 
Gene2Promoter, Genomatix software and the region was cloned 
into pGL4.10 [luc2] promoterless luciferase reporter vector. The 
cloned DNA sequence greatly stimulated the luciferase expression 
which indicates that the sequence has promoter activity (Fig 3.1).  
58 
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Fig. 3.1 NLRP12 promoter activity: (A) The cloned NLRP12 promoter region 
and the schematic representation of luciferase reporter construct generated to 
assess NLRP12 promoter luciferase activity. The arrow indicates the 
transcription start site. (B) HEK 293T cells were transfected with the promoter 
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construct or pGL4.10 [luc2]. 48-hours post transfection, cells were lysed and 
the luciferase activities were determined. pRL-TK renilla luciferase vector was 
used as an internal transfection efficiency control. The error bars represent the 
mean from four independent experiments (** p ≤0.005). 
3.1.2. RelA causes down-regulation of the NLRP12 promoter 
activity 
To determine if there is an effect of NF-κB on the NLRP12 
promoter, we co-transfected the promoter construct (pGL4-
NLRP12-full length) with NF-κB expression plasmids into 
HEK293T cells. Our results showed that RelA causes down-
regulation of the promoter activity while the presence of RelA YA 
ED, which is unable to bind canonical κB sites, did not modify the 
luciferase expression. Furthermore, we did not observe any 
modulation in the NLRP12 promoter activity in response to RelB 
(Fig. 3.2).  
To identify the region that mediates the RelA-mediated 
down-regulation, we transfected the luciferase reporter gene 
plasmids containing different regions of the promoter (Fig. 3.3, 
A), together with RelA or mutant RelA expression plasmids. 
Inside the analyzed promoter region, DNA sequence between the 
bases 530-745 was found to be responsible for the observed 
down-regulation induced by RelA (Fig. 3.3). 
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Fig. 3.2. Effect of NF-κB on the NLRP12 promoter: The plasmid containing 
the 745 bp promoter region (pGL4-NLRP12- full length) co-transfected with 
RelA, RelB or mutant RelA expressing plasmids into HEK 293T cells. After 48 
hours, cells were lysed and the relative luciferase levels were determined. The 
error bars represent the mean of four independent experiments (*p ≤0.05; **p 
≤0.005). 
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Fig.3.3 Effect of RelA on the NLRP12 promoter: HEK 293T cells were 
transfected with the full length (pGL4-NLRP12- full length), pGL4-NLRP12-
299, pGL4-NLRP12-530, pGL4-NLRP12-765 or control pGL4.10 [luc2] 
together with RelA, RelB or with the mutant RelA expressing plasmids. 48 
hours later, cells were lysed and the relative luciferase levels were determined 
as described in “Materials and Methods”. The error bars represent the standard 
error of four separate experiments (*p ≤0.05; ** p ≤0.005). 
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3.1.3. Characterization of NF-κB binding site on the NLRP12 
promoter 
Sequence analysis revealed that NLRP12 promoter region 
contains a “non-consensus”, putative NF-κB binding site. 
Therefore, to verify whether this sequence (between the bases 611 
and 620) was mediating the inhibitory effect of RelA, the 
sequence was mutated by “site-directed mutagenesis” (Fig. 3.4). 
This mutation however, was not able to counteract the effect of 
RelA (Fig. 3.5). As a positive control, another mutation was 
generated to create a consensus NF-κB response sequence inside 
the analyzed NLRP12 promoter region (Fig. 3.4), and this 
mutation did indeed induce a significant up-regulation in response 
to RelA (Fig. 3.5). 
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(A) 
 
 
 
 
 
 
(B) 
 
Fig. 3.4. Site directed mutagenesis of the NLRP12 promoter: (A) The 
putative NF-κB binding site was mutated and the promoter region containing 
the mutation (between the bases 530 and 745) was cloned into pGL4.10 [luc2]. 
The construct is named pGL4-NLRP12Mut-765. To create a consensus NF-κB 
binding site on the promoter, the underlined bases were mutated and the region 
was cloned into pGL4.10 [luc2]. The construct, which was used as a positive 
control, called as pGL4-NLRP12-NFκB-765. (B) The “consensus” NF-κB 
response sequence and the generated mutations on the promoter are shown. 
531-765 bp luciferase [luc2]
pGL4-NLRP12Mut-765
531         CT TCTCCACCCA GAACAGCCAT TGGTGAGTGG GGCAGGGCAG GAGGGAACTG
583 AAGAGTGAGA AAGCATTATT TCAGCAAAAG GTCTTTCCTC CCTTGCTCTC TCCTCCAACC
643 ACTGGCTCAG CCTCTCCGCC CGCTGCCTGT GAATGATGCA ATGGAAGGTG TGCTGGGGTC
703 GCCCTGTGTC CCGTGCATAG GAGCATCTCA GCCTCCAGGT CCTCTCCTTT GGGGCTCACG
763 GCA
AC TTCTGGCC
Mutated putative
NF- B binding site
531 CT TCTCCACCCA GAACAGCCAT TGGTGAGTGG GGCAGGGCAG GAGGGAACTG
583 AAGAGTGAGA AAGCATTATT TCAGCAAAAG GTCTTTCCTC CCTTGCTCTC TCCTCCAACC
643 ACTGGCTCAG CCTCTCCGCC CGCTGCCTGT GAATGATGCA ATGGAAGGTG TGCTGGGGTC
703 GCCCTGTGTC CCGTGCATAG GAGCATCTCA GCCTCCAGGT CCTCTCCTTT GGGGCTCACG
763 GCA
GG GGAATTCC
531-765 bp luciferase [luc2]
pGL4-NLRP12-NF B -765
Mutation creates
consensus
NF- B binding site
+1
+1
Canonical NF- B binding site GGGRNNYYCC
The putative NF- B binding site inside the promoter AGGTCTTTCC
The putative NF- B binding site mutated ACTTCTGGCC
Consensus NF- B binding site generated from GGGGCAGGGC
to obtain GGGGAATTCC
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Fig. 3.5. The activity of mutated NLRP12 promoter region: HEK 293T cells 
were transfected with the wild type (pGL4-NLRP12-765) or mutated (pGL4-
NLRP12Mut-765 and pGL4-NLRP12-NFκB-765) promoter constructs together 
with RelA or mutant RelA expressing plasmids. 48 hours post-transfection, 
cells were lysed and the relative luciferase activity was determined as described 
in “Materials and Methods”. The error bars represent the standard error of three 
separate experiments (*p ≤0.05; ** p ≤0.005). 
3.2. NLRP12 mRNA Level is Decreased by LPS and IFN-  in 
Macrophages 
As mentioned before, NLRP12 expression is down-
regulated following activation by TLR agonists or exposure of 
cells to inflammatory cytokines. We show here that NLRP12 
transcription is down-regulated in human macrophages 
differentiated in vitro from primary human monocytes by GM-
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CSF and treated with the TLR4 agonist LPS (Escherichia coli 
liposaccharide) or stimulated by the cytokine IFN-  for 9 hours 
(Fig. 3.6).  
                      (A)                                                   (B)   
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Fig. 3.6. NLRP12 transcription in human primary macrophages: Primary 
human monocytes from two healthy donors were differentiated into 
macrophages by GM-CSF treatment for 7 days, then incubated with (A) 50 
ng/ml of LPS or (B) 100 U/ml IFN-  for 9 hours, or retained unstimulated 
(indicated as “Resting”). The changes in the NLRP12 transcription were 
analyzed by qRT-PCR. The error bars represent the standard error of three 
replicates. 
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3.3. NLRP12 Transcription Changes During Myeloid Cell 
Differentiation 
To further investigate the dynamic of the NLRP12 
transcription during activation and/or differentiation, we used 
monocytic cell lines as model systems. U937 cells (Human 
histocytic leukemia cell line) were differentiated into macrophage-
like cells by 80 nM, KG1 cells (Human acute myelogenous 
leukemia cell line) were differentiated into dendritic cells by 16 
nM of PMA.  
There are clearly two different time-course of the NLRP12 
down-regulation in response to PMA: while KG1 were responding 
rapidly and the NLRP12 mRNA was already strongly down-
modulated after 4 hours treatment (Fig. 3.7), U937 cells were 
instead up-regulating the expression of NLRP12 after 24 hours 
treatment that was then returning below the basal level after 72 
hours, when the differentiation to macrophages was completed 
and cells were not cycling anymore (Fig. 3.8).  
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Fig. 3.7. NLRP12 mRNA levels during dendritic cell differentiation: 
NLRP12 transcription during differentiation of KG1 monocytic cells into 
dendritic cells by PMA treatment was analyzed by qRT-PCR. The untreated 
KG1 cells are indicated as “Unt”. The error bars represent the standard error of 
three separate experiments with three replicates for each sample (*p ≤0.05; ** p 
≤0.005). 
 
 
 
 
 
 
Fig. 3.8. NLRP12 mRNA levels during macrophage differentiation: 
NLRP12 transcription during differentiation of U937 monocytic cells into 
macrophage-like cells by PMA treatment was analyzed by qRT-PCR. The 
untreated cells were indicated as “Unt”. The error bars represent the standard 
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error of three separate experiments with three replicates for each sample (*p 
≤0.05; ** p ≤0.005). 
In addition, we asked also whether primary human 
monocytes undergoing stimulation by PMA were also regulating 
NLRP12 expression since PMA is not a differentiative agent for 
primary monocytes
77
. Accordingly, primary human monocytes 
isolated from three healthy donors were stimulated with 80 nM of 
PMA for three hours. As shown in Fig. 3.9, in all the cases there 
was a consistent down-modulation of the NLRP12 mRNA 
expression.  
Fig. 3.9. NLRP12 transcription in human primary monocytes treated with 
PMA: Primary human monocytes from different healthy donors were incubated 
with 80 nM of PMA or were left untreated (Unt) for 3 hours. The changes in 
the NLRP12 transcription level were analyzed by qRT-PCR. The error bars 
represent the standard error of three replicates. 
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3.4. U937 Cells Over-expressing NLRP12 Show Different Cell 
Cycle Distribution After PMA Treatment 
It is already known that NLRP12 is expressed in peripheral 
blood leukocytes, predominantly in eosinophils and granulocytes, 
and at lower levels in monocytes. To assess the role of NLRP12 in 
monocytes, we investigated the effect of NLRP12 over-expression 
in monocytic cell line U937. To achieve this, NLRP12 was cloned 
into pcDNA3 expression vector and the green fluorescent protein 
(GFP)-expressing plasmid pEGFP-N1. Using GFP expression 
system, its expression verified in a transient transfection in HeLa 
cells. The expression of 120 kDa NLRP12 protein was shown by 
western blotting, and the cytoplasmic localization was observed 
by fluorescent microscopy (Fig. 3.10).  
U937 cells were then transfected with NLRP12 expressing 
plasmid constructs as described in “Materials and Methods”. 
pcDNA3 and pEGFP-N1 plasmids were used to deliver NLRP12 
into U937 cells. The stable NLRP12 expression was verified by 
qRT-PCR (Fig. 3.11) and flow cytometry analysis (Fig. 3.12). 
The NLRP12 expressing U937 cells were then incubated with 
PMA to analyze the effect of NLRP12 on PMA mediated 
macrophage differentiation. PMA treated U937 cells are adherent, 
non-replicative cells with characteristics of tissue macrophages, 
and this is mediated by a profound change in transcriptome90. 
Although the different morphological features allow to distinguish 
the differentiated cells, there are markers that allow to quantify 
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this process such as CD11b, an integrin associated with cellular 
attachment which is strongly up-regulated by PMA treatment in 
U937 cell line
78
. Moreover, the differentiated cells undergo 
growth arrest in late G1 phase of the cell cycle and express a 
higher amount of the cyclin-dependent kinase inhibitor p21
79
. 
Accordingly, we compared CD11b surface marker and cell cycle 
progression in both Mock-transfected and NLRP12 over-
expressing cells after PMA treatment.  
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(A)                                           (B) 
 
 
 
 
 
 
 
 
(C) 
HeLa cells
pEGFP-N1 (Mock) 
transfected
pEGFPN1-NLRP12
transfected  
Fig. 3.10. Cloning and expression of human NLRP12: (A) Full length 
NLRP12 (3186 bp) was amplified from healthy individual monocyte cDNA by 
PCR, and (B) cloned into enhanced green fluorescent protein (EGFP)-N1 
(pEGFP-N1) vector as C-terminal fusion. NLRP12 expression was confirmed 
by western blot analysis using anti-GFP antibody, and (C) by fluorescence 
microscopy of transient transfected HeLa cells. The EGFP expression is shown 
in the panel, EGFP fused NLRP12 expressing cells are shown in the right in the 
panel. Nuclei are stained blue with DAPI. 
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Fig. 3.11. NLRP12 mRNA expression in stably transfected U937 cells: 
NLRP12 expression was analyzed by qRT-PCR to confirm the stable 
expression of NLRP12 in U937 cells transfected with (A) pcDNA3, or (B) 
pEGFP-N1 constructs. The bars indicate the standard deviation of the three 
replicates.  
 
 
 
 
 
 
 
N
L
R
P
1
2
 m
R
N
A
(r
el
a
ti
v
e
to
1
8
S
 r
R
N
A
)
pEGFP-N1
(Mock)
pEGFPN1-NLRP12
73 
 
   (A) (A) 
 
 
 
(B) 
 
 
 
 
(C) 
 
 
 
 
 
 
 
(A)                                              (B)                                                                     
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
3.5 kb
3  kb
 
 
140 kDa
42 kDa
25 kDa
pEGFP-N1 (Mock) pEGFPN1-NLRP12 
transfected transfected
 
 
140 kDa
42 kDa
25 kDa
 
Wild type (WT) 
pEGFPN1-NLRP12, clone 1 
pEGFPN1-NLRP12, clone 2 
pEGFPN1, clone 1 (Mock) 
C
o
u
n
ts
 
GFP 
 
WT
pEGFP-N1-NLRP12
pEGFP-N1 (Mock)
GFP 
Wild type (WT) 
pEGFPN1-NLRP12, bulk 
pEGFPN1, bulk (Mock) 
C
o
u
n
t
s
 
(A
) 
 
 
 (B
) 
  
 
 
(C
) 
 
 
  
 
  
(A
) 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 (
B
) 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
   
 
       
3
.5
 k
b
3
  k
b
 
 
1
4
0
 k
D
a
4
2
 k
D
a
2
5
 k
D
a
p
E
G
F
P
-N
1
 (
M
o
ck
) 
p
E
G
F
P
N
1
-N
L
R
P
1
2
 
tr
a
n
sf
ec
te
d
tr
a
n
sf
ec
te
d
 
 
1
4
0
 k
D
a
4
2
 k
D
a
2
5
 k
D
a
 
W
il
d
 t
y
p
e 
(W
T
) 
p
E
G
F
P
N
1
-N
L
R
P
1
2
, 
cl
o
n
e 
1
 
p
E
G
F
P
N
1
-N
L
R
P
1
2
, 
cl
o
n
e 
2
 
p
E
G
F
P
N
1
, 
cl
o
n
e 
1
 (
M
o
ck
) 
Counts 
G
F
P
 
 
W
T
p
E
G
F
P
-N
1
-N
L
R
P
1
2
p
E
G
F
P
-N
1
 (
M
o
ck
)
G
F
P
 
W
il
d
 t
y
p
e 
(W
T
) 
p
E
G
F
P
N
1
-N
L
R
P
1
2
, 
b
u
lk
 
p
E
G
F
P
N
1
, 
b
u
lk
 (
M
o
ck
) 
Counts 
U937 cells
pEGFP-N1 (Mock) 
transfected
pEGFPN1-NLRP12
transfected
 
(B) 
Fig. 3.12. Expression of NLRP12-GFP in U937 cells: (A) EGFP fused 
NLRP12 (pEGFPN1-NLRP12) is observed by fluorescence microscope 24 
hours post-transfection of U937 cells. Nuclei are stained blue with DAPI. (B) 
Flow cytometry analysis of EGFP expression to evaluate NLRP12 expression 
level in stably transfected U937 cells. The “bulk” populations are given on the 
left, and the expression in the cell clones are shown on the right, as histograms. 
The results show that NLRP12 over-expression did not 
alter CD11b expression after PMA treatment (Fig. 3.13). 
However, NLRP12 over-expressing cells have shown different 
cell cycle phase distribution after PMA treatment: NLRP12 
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caused a higher percentage of cells accumulating in G2/M phase 
of the cell cycle, which was unexpected (Fig. 3.14). Higher 
concentrations of PMA caused an even higher increase in the 
number of cells in G2/M phase (Table 3.1). An unrelated protein 
(a MHC class I protein) over-expressing, stably transfected U937 
cells was also used as control (Table 3.2). 
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16.33%
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15.27%
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Fig. 3.13. CD11b expression in PMA treated NLRP12 over-expressing 
U937 cells: pcDNA3 (Mock) or pcDNA3-NLRP12 transfected U937 cells 
treated with 40 nM of PMA for 72 hours. The histograms show CD11b 
expression (on the right) relative to isotype controls (on the left). 
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U937 cells G1 phase %
(gate: M1)
S phase %
(gate: M2)
G2/M phase %
(gate: M3)
Mock, PMA treated 78,24 2,82 18,91
NLRP12, PMA treated 52,69 4,51 42,75
Mock, untreated 53,55 34,28 11,76
NLRP12, untreated 56,77 30,41 14,07
 
Fig. 3.14. Analysis of cell cycle progression in NLRP12 over-expressing and 
Mock-transfected cells: pcDNA3-NLRP12 or pcDNA3 (Mock) transfected 
U937 cells were analyzed for cell cycle progression following treatment with 
40 nM PMA for 72 hours. The percentage of cells in G1, S and G2/M phase of 
the cell cycle are indicated in the table. The histograms are representative of 
three independent experiments. 
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U937 cells G1 phase % S phase % G2/M phase %
Mock, 20 nM PMA treated 70,25 4,93 22,64
NLRP12, 20 nM PMA treated 58,63 5,65 32,42
Mock, 40 nM PMA treated 70,32 4,88 22,60
NLRP12, 40 nM PMA treated 54,55 5,66 36,20
U937 cells G1 phase % S phase % G2/M phase %
Mock, 20 nM PMA treated 84,89 2,39 11,90
NLRP12, 20 nM PMA treated 66,46 3,79 28,01
Mock, 40 nM PMA treated 84,67 1,84 12,92
NLRP12, 40 nM PMA treated 62,32 4,34 31,80
U937 cells G1 phase % S phase % G2/M phase %
Mock, untreated 72,55 9,11 14,25
NLRP12, untreated 67,22 11,78 16,80
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Table 3.1. Cell cycle distribution of NLRP12 expressing or Mock-
transfected cells after PMA treatment: After treatment with different doses 
of PMA for 48 or 72 hours, the pcDNA3-NLRP12 or pcDNA3 (Mock) stably 
transfected cells were analyzed for cell cycle distribution by PI staining. The 
percentage of cells in each phase is given. 
U937 cells G1 phase % S phase % G2/M phase %
Mock, PMA treated 78,89 6,60 15,25
NLRP12, PMA treated 66,78 2,93 30,70
Unrelated, PMA treated 76,55 5,51 18,62
Mock, untreated 64,91 15,60 20,99
NLRP12, untreated 60,89 19,56 21,19
Unrelated, untreated 67,46 14,11 19,68  
Table 3.2. Cell cycle distribution of NLRP12 or unrelated protein over-
expressing cells: After 48 hours treatment with 40 nM of PMA, DNA stained 
with PI and the percentage of cells in each phase of the cell cycle was 
determined by flow cytometry analysis. An unrelated protein over-expressing 
U937 cells were used as control. 
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3.5. Immunostaining Reveals Higher Percentage of Cyclin B1 
Positive Interphase Cells in NLRP12 Over-expressing Cells 
The G2/M phase accumulation in NLRP12 over-
expressing cells was also shown by cyclin B1 immunostaining. It 
is already known that as a G2/M phase specific cell cycle marker, 
cyclin B1 expression begins to increase during G2, peaks in 
mitosis, and is rapidly degraded before the cell cycle is 
completed
80
. We have seen that the percentage of cyclin B1 
positively stained cells in interphase was higher in NLRP12 over-
expressing cells when compared with the Mock-transfected cells, 
in both untreated and PMA treated cases (Table 3.3).   
Number of 
counted cells
U937 cells Cyclin B1 (+) cells 
in interphase %
Cells in 
mitosis %
618 Mock, untreated 4,85 2,52
601 Mock, PMA treated 7,32 0,50
620 NLRP12, untreated 6,94 2,05
521 NLRP12, PMA treated 11,9 0,00
 
Table 3.3. Immunostaining for cyclin B1: U937 cells were treated with 40 
nM PMA for 72 hours. The percentages of positively stained interphase cells 
are given. 
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3.6. DNA Content Analysis Shows Unscheduled Cyclin B1 
Expression in Cells Over-expressing NLRP12 
Intracellular cyclin B1 staining was combined with DNA 
content analysis to investigate if the cyclin B1 expression is 
restricted to very late S and G2/M phases of the cell cycle. The 
result show that NLRP12 over-expressing, untreated U937 cells 
express cyclin B1 in an "unscheduled" manner (unrestricted to 
particular phases of the cycle) (Fig. 3.15). 
C
y
cl
in
 B
 e
x
p
re
ss
io
n
DNA content
MOCK NLRP12
F
L
 1
 (
cy
cl
in
B
1
 s
ta
in
in
g
)
FL 3 (PI staining)
C
y
cl
in
 B
 e
x
p
re
ss
io
n
DNA content
MOCK NLRP12
F
L
 1
 (
cy
cl
in
B
1
 s
ta
in
in
g
)
FL 3 (PI staining)
10.4% 14.0%
G2/M
S
G1
G2/M
S
G1
F
L
1
 (
c
y
c
li
n
B
1
 s
ta
in
in
g
)
FL3 (PI staining)
 
Fig. 3.15. Cyclin B1 expression during cell cycle progression: During cell 
cycle progression, cyclin B1 expression in pcDNA3-NLRP12 or pcDNA3 
(Mock) transfected U937 cells was analyzed by flow cytometry. The G1, S and 
G2/M populations were gated (R2) based on the cells stained only with FITC 
conjugated secondary antibody. The DNA content was analyzed by PI staining. 
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3.7. Cyclin B1 and Cyclin A Expression Increase in NLRP12 
Over-expressing cells 
The expression of cyclin B1 was also analyzed by western 
blotting. The protein analyses show higher cyclin B1 expression 
in cells transfected with different (pcDNA3 or pEGFP-N1) 
NLRP12 expression plasmids, and also in different cell clones, 
obtained from “bulk” cell population (Fig. 3.16; Fig. 3.17).  
 
 
 
 
 
 
 
 
Fig. 3.16. Cyclin B1 expression in NLRP12 over-expressing U937 cells: 
Cyclin B1 expression in Mock-transfected (pEGFP-N1, clone 1 and pcDNA3, 
bulk), NLRP12 over-expressing bulk cell population (pcDNA3-NLRP12, bulk) 
and in GFP fused NLRP12 expressing clone cells (pEGFPN1-NLRP12, clone 
1) was analyzed by western blotting. Densitometric analysis of the cyclin B1 
bands are normalized to corresponding GAPDH bands and illustrated in the 
graph. 
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Fig. 3.17. Cyclin B1 expression in NLRP12 over-expressing U937 cell 
clones: Western blot shows expression of cyclin B1 in pEGFP-N1 (Mock) or 
pEGFPN1-NLRP12 transfected bulk cell populations or cell clones. The band 
intensities of cyclin B1 shown in the graph were normalized to that of GAPDH. 
Cyclin A is the other G2/M cyclin whose expression 
begins to be detectable as cells enter S phase, and its level 
increases throughout S and G2 phase, peaking in early mitosis
81
. 
Therefore, the expression of cyclin A was also analyzed in 
NLRP12 over-expressing cells, and likewise cyclin B1, found to 
be upregulated (Fig. 3.19) whereas the expression of G1/S phase 
cyclin, cyclin D1
82 
(Fig. 3.18) remained stable. This observation 
suggests that the over-expression of NLRP12 in U937 monocytic 
cells affects specifically the G2/M phase cyclins.  
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Fig. 3.18. Cyclin D1 expression: Cyclin D1 expression in pEGFP-N1 (Mock) 
and pEGFN1-NLRP12 stably transfected cells was analyzed by western blot. 
Densitometric analysis of cylin D1 bands normalized with GAPDH as loading 
control is shown. 
To understand the mechanisms behind the increased levels 
of G2/M cyclins, we asked whether it is related with the 
proteasome function, since proper progression of the cell cycle 
requires ubiquitin-mediated degradation of the cyclins
86
. The 
proteasome inhibitor MG-132 was used to block proteasome 
activity. The effect of proteasome inhibition on cyclin B1 and 
cyclin A protein levels were analyzed by western blot shown in 
Figure 3.19.  
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Fig. 3.19. Modulation of cylin B1 and cyclin A levels after MG-132 
treatment: pEGFPN1 (Mock) and pEGFN1-NLRP12 stably transfected or 
wild type (WT) U937 cells treated with the proteasome inhibitor MG-132 for 6 
hours or left untreated. Western blot analysis showing the expression of cyclin 
B1 and cyclin A in the MG-132 treated and untreated (indicated with + and -, 
respectively) U937 cells. Densitometric analysis of the western blot. 
immunoreactive bands were normalized to GAPDH.  
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CHAPTER 4 
DISCUSSION 
NLRP12 is a NLR (Nucleotide-binding domain and 
leucine-rich repeat containing) protein which is expressed 
predominantly in cells of myeloid origin. Its expression is down-
regulated in response to pathogens, pathogen products, and 
inflammatory cytokines, and therefore it has been predicted that 
NLRP12 functions in modulating inflammation and immunity. 
Since NLRP12 has been described as a negative regulator of both 
canonical and non-canonical NF-κB activation we asked whether 
NF-κB has a modulatory effect on the NLRP12 promoter.  
Our results suggest that RelA (p65) causes a down-
regulation of the promoter activity, and the region between the 
bases 530-745 appears to be responsible of this down-regulation. 
The NLRP12 promoter region that we have analyzed contains a 
“non-consensus”, putative NF-κB binding site. However, when 
this region was mutagenized, no effect in the promoter expression 
was observed. We therefore concluded that the reduced activity in 
the NLRP12 promoter in response to RelA, is not due to a direct 
84 
 
effect of RelA itself but rather mediated by other, unknown 
factors, possibly induced by RelA.  
Detailed analysis of the canonical and non-canonical NF-
κB pathways in NLRP12 over-expressing monocytic THP-1 cells 
has revealed that nuclear translocation of the canonical NF-κB 
subunits RelA and p50 proceeds normally after stimulation with 
TLR agonist followed by CD40L, however p52 processing from 
NF- B2/p100 and nuclear translocation of p52 is abolished
68
. To 
exert this effect, NLRP12 has been shown to target NF-κB-
inducing kinase (NIK), the kinase responsible for activation of the 
non-canonical pathway
 63 68, 70
. In accordance with these results, 
p52 levels are shown elevated in NLRP12-silenced cells
64
. Thus, 
it can be hypothesized that the stimulation of canonical NF-κB 
pathway can cause the down-regulation of NLRP12 transcription 
which interferes with the inhibitory effect of NLRP12 on the non-
canonical NF-κB pathway (Fig. 4.1). 
The canonical NF-κB pathway is activated rapidly by a 
number of upstream kinases through the IKK (IκB kinase) 
complex
67
. The activation of the canonical pathway results in 
nuclear translocation of RelA which induces a subset of early 
immune response genes. In contrast, the non-canonical activation 
of NF- B displays slower kinetics and is often triggered in 
response to a second signal through TNF (Tumor Necrosis 
Factors) receptor super-family members
67, 68
. Once activated, the 
non-canonical NF-κB pathway drives later events in innate 
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immunity by inducing a different set of inflammatory genes to 
promote the ongoing immune response
83
. In this manner, the 
inhibition of NLRP12 transcription by canonical NF-κB may be 
crucial for the activation of non canonical NF-kB pathway in time, 
for the proper inflammatory response to occur. Further 
characterization of the NLRP12 promoter will likely lead to a 
better understanding of the role of NF-κB on the NLRP12 
transcription.  
 
Fig. 4.1. NLRP12 and NF-κB pathway: NLRP12 negatively controls the non-
canonical NF-κB pathway by interacting with and inducing proteasome-
mediated degradation of NIK. As a result, NF- B2/p100 to p52 processing is 
abolished, and p52-regulated genes are suppressed until NLRP12 expression 
fades. Transcriptional suppression of NLRP12 by RelA can allow the activation 
of non-canonical NF-κB pathway (Modified from Arthur , JC., 2009)68. 
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As mentioned before, functions of NLRs range from 
antigen presentation to pathogen/damage sensing besides 
suppression or modulation of inflammatory signalling. In addition, 
some NLR proteins are also involved in embryonic development. 
NLRP12 is a member of NLR proteins family and its expression is 
restricted to myeloid cells. Although NLRP12 was one of the 
earliest identified NLRPs
60
, the precise function(s) of NLRP12 is 
not fully understood as yet. Despite the studies which indicate a 
role for NLRP12 in regulating NF-κB, the results are conflicting. 
Therefore it can be considered that the function of NLRP12 in 
NF-κB regulation can be dependent on the nature of the stimulus 
and the specific context in which it is given
84
. 
According to its immune cells restricted expression, we 
asked how the NLRP12 expression is modulated during myeloid 
cell differentiation. As in vitro model system for monocyte to 
macrophage differentiation, U937 cells were differentiated into 
macrophage-like cells by PMA treatment. Interestingly, we have 
observed an up-regulation in NLRP12 transcription 24 hours post 
treatment with PMA. The up-regulation of NLRP12 transcription 
has been so far only reported to be induced by NO (nitric oxide) 
treatment
57. As mentioned before, a partial 3’ portion of the gene 
encoding NLRP12 was first identified in the human acute myeloid 
leukaemia (AML) cell line HL60, and called as rno (regulated by 
nitric oxide). Polymorphonuclear leucocytes were shown as the 
primary source of rno in the peripheral blood, and mononuclear 
cells were specified to express the gene constitutively but less 
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than polymorphonuclear leukocytes. When HL-60 cells were 
treated with NO, rno was up-regulated within 24 hours and the 
expression returned to baseline by 48 hours
57
. NO have been 
shown to inhibit the growth of HL-60, and induce HL-60 cells to 
differentiate with an enhanced expression of CD11b, CD14 and 
HLA-DR
85
. Based on these findings, enhancement of rno 
expression has been suggested as having a role in differentiation 
and growth inhibition of leukaemia cells as induced by NO
57
. Our 
study showed that PMA causes the up-regulation of NLRP12 
transcription after 24 hours treatment in U937. However, 
treatment of primary human monocytes with PMA, which is not a 
differentiative agent for primary monocytes
 
but rather causes 
cellular stress
77
, determined the down-regulation of NLRP12 
transcription after three hours treatment. In addition, LPS and 
IFN-  treatment of human primary macrophages also caused 
down-regulation of the transcription, similar to the previous 
findings showing the NLRP12 transcriptional suppression in 
human primary adherent PBMC or granulocytes after treatment 
with TLR agonists and various cytokines
58, 64
. 
Human monocytes can be induced in vitro to differentiate 
to macrophages or to dendritic cells depending on the agents used. 
To study the NLRP12 transcriptional modulation during 
differentiation through these two pathways we took advantage of 
two widely used model systems to study differentiation of 
myeloid cells in vitro: the before mentioned U937 cell line in 
which PMA induces differentiation to macrophage and  the AML 
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cell line KG1 in which PMA treatment induces differentiation 
towards dendritic cells. PMA treatment of KG1 cells caused an 
immediate down regulation of the transcription which proceeded 
through all the differentiation period whereas in the case of U937 
cell line, there was an early up-regulation of NLRP12 mRNA 
followed by down-regulation. These data suggest that the 
modulation of NLRP12 transcription is dependent on the state of 
the myeloid differentiation: NLRP12 transcription is up-regulated 
in the first stages of the macrophage differentiation while is down-
regulated when the differentiation is completed, whereas down-
regulation of the transcription during dendritic cell differentiaton 
is immediate and persistent. Our results obtained from in vitro 
differentiation of primary human monocytes to macrophages by 
GM-CSF or M-CSF (Macrophage Colony-Stimulating Factor) 
treatment, and dendritic cells by GM-CSF and IL-4 treatment also 
suggest that NLRP12 transcription is regulated differently during 
different steps of myeloid cell differentiation. In conclusion, the 
data show a correlation between NLRP12 expression and 
monocyte differentiation. However, it does not tell us whether this 
protein can eventually play a direct role in the process. To address 
this question, NLRP12 was over-expressed in U937 cells. There 
was not apparent difference in the expression of CD11b utilized as 
macrophage differentiation marker following PMA treatment 
between Mock-transfected and NLRP12 over-expressing cells. 
Since PMA treatment of U937 induces G1 cell cycle arrest during 
differentiation, we also analyzed cell cycle progression after PMA 
89 
 
treatment of NLRP12 over-expressing and Mock-transfected cells. 
Surprisingly, G2/M phase accumulation was observed in the cells 
over-expressing NLRP12. Cyclin B1 staining revealed that even 
the mitotic indexes, a measure for the proliferation status of a cell 
population, were comparable between Mock-transfected and 
NLRP12 over-expressing cells. However, the percentage of the 
positively stained interphase cells was higher in NLRP12 over-
expressing cells. This observation was confirmed by cyclin B1 
staining together with DNA content analysis which showed 
increased and unscheduled expression of cyclin B1 in NLRP12 
over-expressing cells: cyclin B1 expression was detected also in 
G1 and S phases of the cell cycle. Increased expression of cyclin 
B1 was also detected by western blot analysis of U937 cells 
transfected with different plasmid constructs. While cyclin A, the 
other G2/M cyclin, was also up-regulated in NLRP12 over 
expressing cells, the expression of cyclin D1, a G1 phase cyclin, 
remained unchanged. These findings suggest that the increased 
expression of NLRP12 induces an up-regulation of the G2/M 
phase specific cyclins. PMA treatment, which causes cell cycle 
arrest, probably leads to transfer of cytoplasmic G2/M cyclins into 
the nucleus and results in a higher amount of cells accumulated in 
G2/M.  
To understand the mechanisms behind the increased levels 
of G2/M cyclins, we asked whether it is related with the 
proteasome function, since polyubiquitination and degradation of 
the cell cycle phase specific cyclins by the proteasome is 
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important for the proper progression of the cell cycle
86
. When we 
used MG-132 proteasome inhibitor, which effectively blocks the 
proteolytic activity of the proteasome complex, we observed that 
the accumulation rate of cyclin B1 and cyclin A were similar 
between NLRP12 over-expressing and Mock-transfected cells, 
even though NLRP12 over-expressing cells have a higher 
expression of both cyclin B1 and cyclin A. The fact that the 
proteasome inhibition rate was similar for NLRP12 over-
expressing and Mock-transfected cells seems to suggest that 
NLRP12 does not interfere with proteasome activity.  
As mentioned before, among the members of NLRs, 
CIITA associates and cooperates with transcription factors in the 
MHC class II promoter so to regulate MHC class II gene 
expression
87
. Recently, NLRC5 was shown as a transcriptional 
regulator of MHC class I genes
42
. CIITA shuttles between the 
nucleus and the cytosol via importin-α-mediated nuclear import 
and CRM1-dependent nuclear export. Similar to CIITA, NLRC5 
was shown trapped in the nucleus upon treatment with the CRM1 
inhibitor leptomycin B (LMB), indicating that NLRC5 also 
shuttles between the cytosol and nucleus, although it localizes in 
the cytoplasm upon over-expresion
42, 87
. Based on these findings, 
one can suggest that the increased level of G2/M cyclins can be 
caused by the transcriptional regulator activity of NLRP12. 
Further investigation is necessary to determine the cellular 
localization of NLRP12. 
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Although we do not know whether NLRP12 has an effect 
on G2/M cyclins in physiological conditions and/or leukemia, 
there are findings about their roles as tumor antigens. It has been 
shown that the peptides derived from cyclin B1 can be displayed 
by HLA class I molecules on tumor cells, then are recognized by 
the cancer patient’s immune system as tumor specific antigens. 
Interestingly, cyclin B1-specific antibody and memory CD4
+
 and 
CD8
+
 T cells have been also found in many healthy individuals 
who have no history of cancer, suggesting a role for cyclin B1 in 
immunity
88
. Furthermore, inactivation of the tumor suppressor 
gene p53 has been shown to be correlated with an abnormal 
expression of cyclin B1 which serves as tumor antigen
89
. It is 
important to highlight that p53 is defective in U937 cells. 
Likewise cyclin B, cyclin A epitope specific CD8
+
 T cells were 
shown to target AML cells
90
. In this regard, the role of NLRP12 in 
the cyclin related immunity is worthwhile to investigate, since 
there is strong evidence indicating a role for NLRP12 in colon 
inflammation and tumorigenesis
69, 70
. 
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